Abstract
Human T-cell lymphotropic virus type 1 (HTLV-1), is the causative agent of adult T-cell leukemia/lymphoma (ATLL) and a variety of immune-mediated disorders (Table 1). Currently, HTLV-1 infection occurs worldwide with endemic regions of higher prevalence. Natural transmission of these viruses occurs through cell-associated routes that include: orally from breast feeding, sexual contact, and by exposure to infected blood or whole cell blood products. While the molecular events of virus replication are beginning to be unraveled and knowledge about HTLV-1-associated diseases has increased, there remain many questions regarding the pathogenesis of the diseases associated with this complex retrovirus. In this chapter, we will focus on the pathogenesis and clinical presentation of ATLL with emphasis on new information regarding the viral etiology, pathologic lesions, patient susceptibility factors, host immune responses, and, in particular, the role of cytokines in the development of ATLL. The epidemiology and diseases associated with HTLV-1 are well known; however, the molecular mechanisms used by the virus to establish persistent infection and subsequently facilitate lymphocyte proliferation while circumventing immune elimination, remain less well defined.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide seroepidemiological study. Int J Cancer 1982; 29:631.
Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retro virus from cell lines of human T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79:2031–2035.
Yoshida M, Sciki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984; 81:2534–2537.
Takatsuki K, Uchiyama T, Sagawa K, Yodoi J. Adult T-cell leukemia in Japan. In: Seno S, Takaku F, Irino S, editors. Topics in Hematology. Amsterdam: Excerpta Medica, 1977: 73–77.
Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: Clinical and hematologie features of 16 cases. Blood 1977; 50(3):481–492.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77(12):7415–7419.
Hinuma Y, Nagata K, Hanaoka M, et al. Adult T Cell Leukemia: Antigens in an ATL cell line and detection of antibodies to antigen in human sera. Proc Natl Acad Sci U S A 1981; 78:6476–6480.
Miyoshi I, Kubonishi I, Sumida M et al. A novel T-cell line derived from adult T-cell leukemia. Gann 1980; 71(1):155, 156.
Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y. A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gann 1981; 72(6):978–981.
Gessain A, Mahieux R. A virus called HTLV-1. Epidemiological aspects. Presse Med 2000; 29(40): 2233–2239.
Blattner W, Kalyanaraman V, Robert-Guroff Met al. The human type-C retrovirus, HTLV, in blacks from the Caribbean region and relationchip to adult T-cell leukemia/lymphoma. Int J Cancer 1982; 30:257.
SaxingerWC, Blattner W, Levine Pet al. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. Science 1984; 225:1473.
Reeves W, Saxinger C, Brenes M, et al. Human T-cell lymphotropic virus type I (HTLV-I) and risk factors in metropolitan Panama. Am J Epidemiol 1988; 127:539.
Merino F, Robert-Guroff M, Clark J, Biondo-Bracho M, Blattner W, Gallo RC. Natural antibodies to human T-cell leukemia/lymphoma virus in healthy Venezuelan populations. Int J Cancer 1984; 34:501.
Asher DM, Goudsmit J, Pomeroy K, et al. Antibodies to HTLV-I in populations of the southwestern Pacific. J Med Virol 1988; 26:339.
Anderson DC, Epstein J, Pierik L, et al. Licensure of screening tests for antibody to human T-cell lymphotropic virus type I. Morb Mort Weekly Report 1988; 37:736.
Nagai M, Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 2003; 9(2):228–235.
Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000; 18(l):109–119.
Courouce AM, Pillonel J, Lemaire JM, Saura C. HTLV testing in blood transfusion. Vox Sang 1998; 74Suppl 2:165–169.
Ferreira OCJr., Planelles V, Rosenblatt JD. Human T-cell leukemia viruses: Epidemiology, biology, and pathogenesis. Blood Rev 1997; 11(2):91–104.
Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II-and I-infected blood donors. Arch Intern Med 1999; 159:1485–1491.
Schreiber GB, Murphy EL, Horton JA, et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and-II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14(3):263–271.
Yamamoto N, Okada M, Koyanagi Y, Kannagi M, Hinuma Y Transformation of human Leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science 1982; 217(20): 737–739.
Hino S, Yamaguchi K, Katamine S, et al. Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 1985; 76(6):474–480.
Hino S. Milk-borne transmission of HTLV-I as a major route in the endemic cycle. Acta Paediatr Jpn 1989; 31(4):428–435.
Khabbaz RF, Douglas JM, Judson FN, et al. Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA. J Infect Dis 1990; 162(l):241–244.
Khabbaz RF, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326(6):375–380.
Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients. Vox Sang 1984; 46(5):245–253.
Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis 1993; 167:57–65.
Yamaguchi K, Takatsuki K. Adult T cell leukaemia-lymphoma. Clin Haematol 1993; 6(4):899–915.
Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994; 343(8891):213–216.
Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type I infection on nonHodgkin’s lymphoma incidence. J Nat Cancer Inst 1995; 87:1009–1014.
White JD, Zaknoen SL, Kastensportes C, et al. Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer 1995; 75:1598–1607.
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma. A report from the Lymphoma Study Group (1984-1987). Br J Haematol 1991; 79(3): 428–437.
Yamaguchi K, Nishimura H, Kohrogi H, Jono M, Miyamoto Y, Takatsuki K. A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood 1983; 62(4):758–766.
Kawano F, Yamaguchi K, Nishimura H, Tsuda H, Takatsuki K. Variation in the clinical courses of adult T-cell leukemia. Cancer 1985; 55(4):851–856.
Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 2003; 17(l):26–38.
Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995; 86(10):3619–3639.
Hollsberg P, Wucherpfennig KW, Ausubel LJ, Calvo V, Bierer BE, Hafler DA. Characterization of HTLV-1 In Vivo Infected T Cell Clones IL-2-independent Growth of Nontransformed T Cells. J Immunol 1992; 148:3256–3263.
Gatza ML, Watt JC, Marriott SJ. Cellular transformation by the HTLV-I Tax protein, a jack-of-alltrades. Oncogene 2003; 22(33):5141–5149.
Franchini G, Wong-Staal F, Gallo RC. Human T-cell leukemia virus (HTLV-I) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. Proc Natl Acad Sci U S A 1984; 81(19):6207–6211.
Korber B, Okayama A, Donnelly R, Tachibana N, Essex M. Polymerase chain reaction analysis of defective human T-cell leukemia virus type 1 proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol 1991; 65(10):5471–5476.
Gessain A, Barin F, Vernant J, et al. Antibodies to human T lymphotropic virus type 1 in patients with tropical spastic paresis. Lancet 1985; 2:407–410.
Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; i:1031–1032.
Adedayo O, Grell G, Bellot P. Hospital admissions for human T-cell lymphotropic virus type-1 (HTLV-1) associated diseases in Dominica. Postgrad Med J 2003; 79(932):341–344.
Kasahata N, Shiota J, Miyazawa Y, Nakano I, Murayama S. Acute human T-lymphotropic virus type 1-associated myelopathy: A clinicopathologic study. Arch Neurol 2003; 60(6):873–876.
Furukawa Y, Kubota R, Eiraku N, et al. Human T-cell lymphotropic virus type I (HTLV-I)-related clinical and laboratory findings for HTLV-I-infected blood donors. J Acquir Immune Defic Syndr 2003; 32(3):328–334.
Kiwaki T, Umehara F, Arimura Y et al. The clinical and pathological features of peripheral neuropathy accompanied with HTLV-I associated myelopathy. J Neurol Sci 2003; 206(1): 17–21.
Nagai M, Usuku K, Matsumoto W et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4(6):586–593.
Nitta T, Tanaka M, Sun B, Hanai S, Miwa M. The genetic background as a determinant of human T-cell leukemia virus type 1 proviral load. Biochem Biophys Res Commun 2003; 309(1): 161–165.
Bangham CR. Human T-lymphotropic virus type 1 (HTLV-1): Persistence and immune control. Int J Hematol 2003; 78(4):297–303.
Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 2003; 84(Pt 12):3177–3189.
Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1 — associated myelopathy (HAM/TSP). Blood 2002; 99(l):88–94.
Kitze B, Usuku K. HTLV-1-mediated immunopathological CNS disease. Curr Top Microbiol Immunol 2002; 265:197–211.
Osame M, Janssen R, Kubota H et al. Nationwide survey of HTLV-I-associated Myelopathy in Japan: Association with blood transfusion. Ann Neurol 1990; 28:50–56.
Daenke S, Nightingale S, Cruickshank JK, Bangham CRM. Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates. J Virol 1990; 64(3):1278–1282.
Evangelista A, Maroushek S, Minnigan H, et al. Nucleotide sequence analysis of a provirus derived from an individual with tropical spastic paraparesis. Microb Pathog 1990; 8(4):259–278.
Gould KG, Bangham CR. Virus variation, escape from cytotoxic T lymphocytes and human retroviral persistence. Semin Cell Dev Biol 1998; 9:321–328.
Mahieux R, Ibrahim F, Mauclere P et al. Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: Identification of a new and distinct HTLV-1 molecular subtype in central Africa and in pygmies. J Virol 1997; 71(2):1317–1333.
Saito M, Furukawa Y, Kubota R, et al. Frequent mutation in pX region of HTLV-1 is observed in HAM/TSP patients, but is not specifically associated with the central nervous system lesions. J Neurovirol 1995; 1(3–4): 286–294.
Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-1 Uveitis: A distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992; 83:236–239.
Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I [letter]. Lancet 1989; i(8635):441.
Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjogren’ syndrome. Lancet 1994; 344:1116–1119.
Lagrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990; 336(8727): 1345–1347.
Leonmonzon M, Illa I, Dalakas MC. Polymyositis in patients infected with human T-cell leukemia virus type I: The role of the virus in the cause of the disease. Ann Neurol 1994; 36:643–649.
Ohshima K, Kikuchi M, Masuda Y, et al. Human T-cell leukemia virus type I associated lymphadenitis. Cancer 1992; 69(l):239–248.
Kimura I, Tsubota T, Tada S, Sogawa J. Presence of antibodies against adult T cell leukemia antigen in the patients with chronic respiratory diseases. Acta Med Okayama 1986; 40(6):281–284.
Xu RZ, Gao QK, Wang SJ, et al. Human acute myeloid leukemias may be etiologically associated with new human retroviral infection. Leuk Res 1996; 20(6):449–455.
Yajima A, Kawada A, Aragane Y, Tezuka T. Detection of HTLV-I proviral DNA in sarcoidosis. Dermatology 2001; 203(l):53–56.
Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT1 is a receptor for HTLV Cell 2003; 115(4):449–459.
Bukrinsky MI, Sharova N, Dempsey MP et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A 1992; 89(14):6580–6584.
Green PL, Chen IS Y. Regulation of human T cell leukemia virus expression. FASEB J 1990; 4:169–175.
Kiyokawa T, Sciki M, Iwashita S, Imagawa K, Shimizu F, Yoshida M. p27x-III and p21x-III, proteins encoded by the pX sequence of human T-cell leukemia virus type 1. Proc Natl Acad Sci USA 1985; 82:8359–8363.
Sciki M, Hikikoshi A, Taniguchi T, Yoshida M. Expression of the pX Gene of HTLV-1: General Splicing Mechanism in the HTLV Family. Science 1985; 228:1532–1534.
Felber BK, Paskalis H, Kleinmanewing C. The pX Protein of HTLV-1 is a Transcriptional Activator of its Long Terminal Repeats. Science 1985; 229:675–679.
Sodroski J, Rosen C, Goh WC, Haseltine W. A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. Science 1985; 228(4706): 1430–1434.
Kimzey AL, Dynan WS. Identification of a human T-cell leukemia virus type I tax peptide in contact with DNA. J Biol Chem 1999; 274:34226–34232.
Lenzmeier BA, Baird EE, Dervan PB, Nyborg JK. The tax protein-DNA interaction is essential for HTLV-I transactivation in vitro. J Mol Biol 1999; 291(4):731–744.
Perini G, Wagner S, Green MR. Recognition of bZIP proteins by the human T-cell leukaemia virus transactivator Tax. Nature 1995; 376:602–605.
Maruyama M, Shibuya H, Harada H et al. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. Cell 1987; 48(2):343–350.
Wolin M, Kornuc M, Hong C, et al. Differential effect of HTLV infection and HTLV Tax on interleukin 3 expression. Oncogene 1993; 8(7): 1905–1911.
Li-Weber M, Giaisi M, Chlichlia K, Khazaie K, Krammer PH. Human T cell leukemia virus type I Tax enhances IL-4 gene expression in T cells. Eur J Immunol 2001; 31(9):2623–2632.
Muraoka O, Kaisho T, Tanabe M, Hirano T. Transcriptional activation of the interleukin-6 gene by HTLV-1. Immunology Letters 1993; 37(2–3):159–165.
Mori N, Mukaida N, Ballard DW, Matsushima K, Yamamoto N. Human T-cell leukemia virus type I Tax transactivates human interleukin 8 gene through acting concurrently on AP-1 and nuclear factorkappaB-like sites. Cancer Res 1998; 58(17):3993–4000.
Mori N, Prager D. Transactivation of the interleukin-1 alpha promoter by human Tcell leukemia virus type I and type II tax proteins. Blood 1996; 87(8):3410–3417.
Miyatake S, Sciki M, Malefijt RD et al. Activation of T cell-derived lymphokine genes in T cells and fibroblasts: effects of human T cell leukemia virus type I p40x protein and bovine papilloma virus encoded E2 protein. Nucleic Acids Res 1988; 16(14A):6547–6566.
Cowan EP, Alexander RK, Daniel S, Kashanchi F, Brady JN. Induction of tumor necrosis factor alpha in human neuronal cells by extracellular human T-cell lymphotropic virus type 1 Tax(l). J Virol 1997; 71(9):6982–6989.
Lindholm PF, Reid RL, Brady JN. Extracellular Tax Protein Stimulates Tumor Necrosis Factor-B and Immunoglobulin Kappa Light Chain Expression in Lymphoid Cells. J Virol 1992; 66:1294–1302.
Duyao MP, Kessler DJ, Spicer DB, et al. Transactivation of the c-myc Promoter by Human T Cell Leukemia virus Type 1 tax is Mediated by NFkB. J Biol Chem 1992; 267:16288–16291.
Fujii M, Sassone-Corsi P, Verma I. c-fos promotor trans-activation of cAMP on IL-2 stimulated gene expression. Proc Natl Acad Sci U S A 1988;8526–8530.
Ratner L. Regulation of expression of the c-sis proto-oncogene. Nucleic Acids Res 1989; 17(11): 4101–4115.
Fujii M, Tsuchiya H, Chuhjo T, Akizawa T, Sciki M. Interaction of HTLV-1 Tax1 with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes. Genes Dev 1992; 6(11):2066–2076.
Li CC, Ruscetti FW, Rice NRet al. Differential expression of Rel family members in human T-cell leukemia virus type I-infected cells: Transcriptional activation of c-rel by Tax protein. J Virol 1993; 67:4205–4213.
Jeang KT, Widen SG, Semmes OJ, Wilson SH. HTLV-1 Trans-Activator Protein, Tax, Is a TransRepressor of the Human B-Ploymerase Gene. Science 1990; 247:1082, 1083.
Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000; 96(1):275–281.
Tsukahara T, Kannagi M, Ohashi T et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73(10):7981–7987.
Lemasson I, Roberthebmann V, Hamaia S, Dodon MD, Gazzolo L, Devaux C. Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40(tax). J Virol 1997; 71(3):1975–1983.
Ressler S, Morris GF, Marriott SJ. Human T-cell leukemia virus type 1 Tax transactivates the human proliferating cell nuclear antigen promoter. J Virol 1997; 71(2):1181–1190.
Ye J, Silverman L, Lairmore MD, Green PL. HTLV-1 Rex is required for viral spread and persistence in vivo but is dispensable for cellular immortalization in vitro. Blood 2003; 102(12):3963–3969.
Akagi T, Takeda I, Oka T, Ohtsuki Y, Yano S, Miyoshi I. Experimental infection of rabbits with human T-cell leukemia virus type 1. Jpn J Cancer Res 1985; 76:86–94.
Lairmore MD, Roberts B, Frank D, Rovnak J, Weiser MG, Cockerell GL. Comparative biological responses of rabbits infected with human T-lymphotropic virus Type I isolates from patients with lymphoproliferative and neurodegenerative disease. Int J Cancer 1992; 50:124–130.
Murata N, Hakoda E, Machida H, et al. Prevention of human T cell lymphotropic virus type 1 infection in Japanese macaques by passive immunization. Leukemia 1996; 10(12):1971–1974.
Nakamura H, Hayami M, Ohta Y, et al. Protection of Cynomolgus Monkeys Against Infection by Human T-Cell leukemia Virus Type-1 by Immunization with Viral env Gene Products Produced in Escerichia coli. Int J Cancer 1987; 40:403–407.
Suga T, Kameyama T, Shimotohno K, et al. Infectiion of Rats with HTLV-1: A Small-Animal Model for HTLV-1 Carriers. Int J Cancer 1991; 49:764–769.
Ibrahim F, Fiette L, Gessain A, Buisson N, Dethe G, Bomford R. Infection of rats with human T-cell leukemia virus type-1: Susceptibility of inbred strains, antibody response and provirus location. Int J Cancer 1994; 58:446–451.
Furuta RA, Sugiura K, Kawakita S, et al. Mouse Model for the Equilibration Interaction between the Host Immune System and Human T-Cell Leukemia Virus Type 1 Gene Expression. J Virol 2002; 76(6):2703–2713.
Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M. Cell-free entry of human t-cell leukemia virus type 1 to mouse cells. Jpn J Cancer Res 2001; 92(4):410–416.
Leendertz FH, Boesch C, Junglen S, Pauli G, Ellerbrook H. Characterization of a new simian T-lymphocyte virus type 1 (STLV-1) in a wild living chimpanzee (Pan troglodytes verus) from Ivory Coast: evidence of a new STLV-1 group? AIDS Res Hum Retroviruses 2003; 19(3):255–258.
Niphuis H, Verschoor EJ, Bontjer I, Peeters M, Heeney JL. Reduced transmission and prevalence of simian T-cell lymphotropic virus in a closed breeding colony of chimpanzees (Pan troglodytes verus). J Gen Virol 2003; 84(Pt 3):615–620.
Gabet AS, Gessain A, Wattel E. High simian T-cell leukemia virus type 1 proviral loads combined with genetic stability as a result of cell-associated provirus replication in naturally infected, asymptomatic monkeys. Int J Cancer 2003; 107(l):74–83.
Mahieux R, Chappey C, Georges-Courbot MC, et al. Simian T-cell lymphotropic virus type 1 from Mandrillus sphinx as a simian counterpart of human T-cell lymphotropic virus type 1 subtype D. J Virol 1998; 72(12):10316–10322.
Mortreux F, Kazanji M, Gabet AS, de Thoisy B, Wattel E. Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus). J Virol 2001; 75(2):1083–1089.
Kazanji M, Tartaglia J, Franchini G et al. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol 2001; 75(13):5939–5948.
Kazanji M. HTLV type 1 infection in squirrel monkeys (Saimiri sciureus): A promising animal model for HTLV type 1 human infection. AIDS Res Hum Retroviruses 2000; 16(16):1741–1746.
Hakata Y, Yamada M, Shida H. Rat CRM1 Is Responsible for the Poor Activity of Human T-Cell Leukemia Virus Type 1 Rex Protein in Rat Cells. J Virol 2001; 75(23):11515–11525.
Hanabuchi S, Ohashi T, Koya Y, et al. Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade. J Virol 2000; 74(1):428–435.
Kasai T, Ikeda H, Tomaru U, et al. A rat model of human T lymphocyte virus type I (HTLV-I) infection: In situ detection of HTLV-I provirus DNA in microglia/macrophages in affected spinal cords of rats with HTLV-1-induced chronic progressive myeloneuropathy. Acta Neuropathol 1999; 97:107–112.
Sun B, Fang J, Yagami K, et al. Age-dependent paraparesis in WKA rats: evaluation of MHC k-haplotype and HTLV-1 infection. J Neurol Sci 1999; 167(1):16–21.
Hasegawa A, Ohashi T, Hanabuchi S, et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol 2003; 77(5):2956–2963.
Kotani S, Yoshimoto S, Yamato K, et al. Serial transmission of human T-cell leukemia virus type 1 by blood transfusion in rabbits and its prevention by use of x-irradiated stored blood. Int J Cancer 1986; 37:843–847.
Uemura Y, Kotani S, Yoshimoto S, et al. Oral transmission of human T-cell leukemia Virus type-1 in the rabbit. Jpn J Cancer Res 1986; 77:970–973.
Mosier DE. Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. Adv Immunol 1991; 50:303–325.
Feuer G, Stewart SA, Baird SM, Lee F, Feuer R, Chen IS. Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. J Virol 1995; 69(2): 1328–1333.
Liu Y, Dole K, Stanley JR, et al. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leuk Res 2002; 26(6):561–567.
Takaorikondo A, Imada K, Yamamoto I, et al. Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells. Blood 1998; 91:4747–4751.
Furlan R, Salazargrueso EF, Martino G, et al. Human T-cell lymphotropic virus type-I infection in the severe combined immunodeficiency mouse. J Med Virol 1996; 49(2):77–82.
Feuer G, Fraser JK, Zack JA, Lee F, Feuer R, Chen IS Y Human T-cell leukemia virus infection of human hematopoietic progenitor cells: Maintenance of virus infection during differentiation in vitro and in vivo. J Virol 1996; 70(6):4038–4044.
Nerenberg MI. An HTLV-I transgenic mouse model: role of the tax gene in pathogenesis in multiple organ systems. Curr Top Microbiol Immunol 1990; 160:121–128.
Kitajima I, Hanyu N, Kawahara K, et al. Ribozyme-based gene cleavage approach to chronic arthritis associated with human T cell leukemia virus type I — Induction of apoptosis in synoviocytes by ablation of HTLV-1 tax protein. Arthritis Rheum 1997; 40:2118–2127.
Nerenberg MI, Minor T, Price J, Ernst DN, Shinohara T, Schwarz H. Transgenic thymocytes are refractory to transformation by the human T-cell leukemia virus type I tax gene. J Virol 1991; 65(6): 3349–3353.
Iwakura Y, Saijo S, Kioka Y, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol 1995; 155(3): 1588–1598.
Green JE. trans activation of nerve growth factor in transgenic mice containing the human T-cell lymphotropic virus type I tax gene. Mol Cellular Biol 1997; 11(9):4635–4641.
Benvenisty N, Ornitz DM, Bennett GL, et al. Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/cmyc and Ig/tax genes. Oncogene 1992; 7(12):2399–2405.
Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1995; 92(4):1057–1061.
Grossman WJ, Ratner L. Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood 1997; 90(2): 783–794.
Apte RN, Voronov E. Interleukin-1—a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12(4):277–290.
Horn F, Henze C, Heidrich K. Interleukin-6 signal transduction and lymphocyte function. Immunobiology 2000; 202(2): 151–167.
Carvalho EM, Bacellar O, Porto AF, Braga S, Galvao-Castro B, Neva F. Cytokine profile and immunomodulation in asymptomatic human Tlymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr 2001; 27(l):1–6.
Furuya T, Nakamura T, Fujimoto T, et al. Elevated levels of interleukin-12 and interferon-gamma in patients with human T lymphotropic virus type I associated myelopathy. J Neuroimmunol 1999; 95:185–189.
Scholz C, Hafler DA, Hollsberg P. Downregulation of IL-10 secretion and enhanced antigen-presenting abilities following HTLV-I infection of T cells. J Neuroscience Res 1996; 45:786–794.
Tsuruma T, Yagihashi A, Torigoe T, et al. Interleukin-10 inhibited the expression of tumor antigens and major histocompatibility complex antigen on EJ-ras oncogene transformants. Artificial Organs 1996; 20(8):895–897.
Hanon E, Goon P, Taylor GP, et al. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood 2001; 98(3):721–726.
Mitre E, Thompson RW, Carvalho EM, Nutman TB, Neva FA. Majority of interferon-gamma-producing CD4+ cells in patients infected with human T cell lymphotrophic virus do not express tax protein. J Infect Dis 2003; 188(3):428–432.
Chung HK, Young HA, Goon PK, et al. Activation of interleukin-13 expression in T cells from HTLV-1-infected individuals and in chronically infected cell lines. Blood 2003; 102(12): 4130–4136.
Pawelec G. Tumour escape: Antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53(3):262–274.
Mitra-Kaushik S, Harding JC, Hess J, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 tax transgenic mice and tax tumor transplants. Blood 2004; 104(3): 802–809.
Persaud D, Munoz JL, Tarsis SL, Parks ES, Parks WP. Time course and cytokine dependence of human T-cell lymphotropic virus type 1 T-lymphocyte transformation as revealed by a microtiter infectivity assay. J Virol 1995; 69:6297–6303.
Tatewaki M, Yamaguchi K, Matsuoka M, et al. Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T-cell lymphotropic virus type 1 Tax. Blood 1995; 86:3109–3117.
Copeland KFT, Heeney JL. T helper cell activation and human retroviral pathogenesis. Microbiol Rev 1996; 60(4):722.
Biddison WE, Kubota R, Kawanishi T et al. Human T cell leukemia virus type I (HTLV-l)-specific CD8(+) CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol 1997; 159(4):2018–2025.
Giraudon P, Buart S, Bernard A, Belin ME Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes. [Review] [23 refs]. Molecular Psychiatry 1997; 2(2): 107–110, 84.
Miyazato A, Kawakami K, Iwakura Y, Saito A. Chemokine synthesis and cellular inflammatory changes in lungs of mice bearing p40tax of human T-lymphotropic virus type 1. Clin Exp Immunol 2000; 120(l):113–124.
Li XH, Gaynor RB. Mechanisms of NF-kappaB activation by the HTLV type 1 tax protein. AIDS Res Hum Retroviruses 2000; 16(16):1583–1590.
Ng PW, Iha H, Iwanaga Y, et al. Genome-wide expression changes induced by HTLV-1 Tax: Evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappaB activation. Oncogene 2001; 20(33):4484–4496.
Dodon MD, Li Z, Hamaia S, Gazzolo L. Tax protein of human T-cell leukaemia virus type 1 induces interleukin 17 gene expression in T cells. J Gen Virol 2004; 85(Pt 7): 1921–1932.
Kuo YL, Tang Y, Harrod R, Cai P, Giam CZ. Kinase-inducible domain-like region of HTLV type 1 tax is important for NF-kappaB activation. AIDS Res Hum Retroviruses 2000; 16(16): 1607–1612.
Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappaB site. J Immunol 2001; 166(4):2602–2609.
Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC. NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 2001; 276(44):40385–40388.
Shimizu T, Kawakita S, Li QH, Fukuhara S, Fujisawa J. Human T-cell leukemia virus type 1 Tax protein stimulates the interferon-responsive enhancer element via NF-kappaB activity. FEBS Lett 2003; 539(l-3):73–77.
O’Mahony AM, Montano M, Van Beneden K, Chen LF, Greene WC. Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem 2004; 279(18):18137–18145.
Sun SC, Harhaj EW, Xiao G, Good L. Activation of I-kappaB kinase by the HTLV type 1 tax protein: mechanistic insights into the adaptor function of IKKgamma. AIDS Res Hum Retroviruses 2000; 16(16):1591–1596.
Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 2001; 12(2–3):207–217.
Yin MJ, Christerson LB, Yamamoto Y, et al. HTLV-I tax protein binds to MEKK1 to stimulate I kappa B kinase activity and NF-kappa B activation. Cell 1998; 93:875–884.
Li XH, Murphy KM, Palka KT, Surabhi RM, Gaynor RB. The human T-cell leukemia virus type-1 Tax protein regulates the activity of the I kappa B kinase complex. J Biol Chem 1999; 274:34417–34424.
Suzuki T, Hirai H, Fujisawa J, Fujita T, Yoshida M. A trans-activator Tax of human T-cell leukemia virus type 1 binds to NFkappa B p50 and serum response factor (SRF) and associates with enhancer DNAs of the NF-kappa B site and CArG box 5014. Oncogene 1993; 8(9):2391–2397.
Good L, Maggirwar SB, Harhaj EW, Sun SC. Constitutive dephosphorylation and activation of a member of the nuclear factor of activated T cells, NF-AT1, in Tax-expressing and type I human T-cell leukemia virus-infected human T cells 5284. J Biol Chem 1997; 272(3): 1425–1428.
Rivera I, Harhaj EW, Sun SC. Involvement of NF-AT in type I human T-cell leukemia virus Tax-mediated Fas ligand promoter transactivation. J Biol Chem 1998; 273(35):22382–22388.
Georges SA, Giebler HA, Cole PA, Luger K, Laybourn PJ, Nyborg JK. Tax recruitment of CBP/p300, via the KIX domain, reveals a potent requirement for acetyltransferase activity that is chromatin dependent and histone tail independent. Mol Cell Biol 2003; 23(10):3392–3404.
Lemasson I, Polakowski NJ, Laybourn PJ, Nyborg JK. Transcription regulatory complexes bind the human T-cell leukemia virus 5’ and 3’ long terminal repeats to control gene expression. Mol Cell Biol 2004; 24(14):6117–6126.
Mori N, Morishita M, Tsukazaki T, et al. Human T-cell leukemia virus type I oncoprotein Tax represses Smaddependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. Blood 2001; 97(7):2137–2144.
Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of smad proteins with smadbinding element. J Biol Chem 2002; 277(37):33766–33775.
Yamada Y, Sugawara K, Hata T, et al. Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: Expression of IL-15 receptor alpha on ATL cells. Blood 1998; 91:4265–4272.
Teshigawara K, Maeda M, Nishino K, et al. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 1985; 2(1): 17–26.
Yodoi J, Tagaya Y, Masutani H, Maeda Y, Kawabe T. IL-2 receptor and Fc epsilon R2 gene activation in lymphocyte transformation: possible roles of ATL-derived factor. Int Symp Princess Takamatsu Cancer Res Fund 1988; 19:73–86.
Leung K, Nabel GJ. HTLV-1 trans activator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature 1988; 333(6175):776–778.
Collins ND, D’Souza C, Albrecht B, et al. Proliferation response to interleukin-2 and Jak/Stat activation of T cells immortalized by human T-cell lymphotropic virus type 1 is independent of open reading frame I expression. J Virol 1999; 73(11):9642–9649.
Azimi N, Jacobson S, Leist T, Waldmann TA. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: Implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 1999; 163:4064–4072.
Waldmann TA. T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma. Ann Oncol 2000; 11Suppl 1:101–106.
Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 2003; 102(l):284–288.
Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the janus kinase 3-stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol 2000; 165(9):5097–5104.
Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19(15):3562–3571.
Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004; 118:83–100.
Wilson KC, Center DM, Cruikshank WW, Zhang Y. Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T cell PDZ domain-containing protein. Virology 2003; 306(l):60–67.
Moriuchi H, Moriuchi M, Fauci AS. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: Implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med 1998; 187:1689–1697.
Calabresi PA, Martin R, Jacobson S. Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J Neurovirology 1999; 5:102–108.
Mori N, Ueda A, Ikeda S, et al. Human T-cell leukemia virus type I tax activates transcription of the human monocyte chemoattractant protein-1 gene through two nuclear factor-kappaB sites. Cancer Res 2000; 60(17):4939–4945.
Hasegawa H, Nomura T, Kohno M et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 2000; 95(l):30–38.
Seki M, Higashiyama Y, Kadota J, et al. Elevated levels of soluble adhesion molecules in sera and BAL fluid of individuals infected with human T-cell lymphotropic virus type1. Chest 2000; 118(6):1754–1761.
Lewis MJ, Gautier VW, Wang XP, Kaplan MH, Hall WW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol 2000; 165(7):4127–4132.
Sharma V, Lorey SL. Autocrine role of macrophage inflammatory protein-1 beta in human T-cell lymphotropic virus type-I tax-transfected Jurkat T-cells. Biochem Biophys Res Commun 2001; 287(4):910–913.
Ruckes T, Saul D, Van Snick J, Hermine O, Grassmann R. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood 2001; 98(4):1150–1159.
Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99(5):1505–1511.
Imaizumi Y, Sugita S, Yamamoto K et al. Human T cell leukemia virus type-I Tax activates human macrophage inflammatory protein-3 alpha/CCL20 gene transcription via the NF-kappa B pathway. Int Immunol 2002; 14(2): 147–155.
Mori N, Krensky AM, Ohshima K, et al. Elevated expression of CCL5/RANTES in adult T-cell leukemia cells: possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax. Int J Cancer 2004; 111(4):548–557.
Tanaka Y, Mine S, Figdor CG, et al. Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells. Blood 1998; 91(10):3909–3919.
Arai M, Ohashi T, Tsukahara T, et al. Human T-cell leukemia virus type 1 Tax protein induces the expression of lymphocyte chemoattractant SDF-1/PBSF. Virology 1998; 241:298–303.
Johnson AN, Newfeld SJ. The TGF-beta family: signaling pathways, developmental roles, and tumor suppressor activities. Scientific World Journal 2002; 2:892–925.
Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12(l):22–29.
Ellenrieder V, Buck A, Gress TM. TGFbeta-regulated transcriptional mechanisms in cancer. Int J Gastrointest Cancer 2002; 31(l-3):61–69.
Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296(5573): 1646–1647.
Kim SJ, Winokur TS, Lee HD, et al. Overexpression of transforming growth factor-beta in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene. Mol Cell Biol 1991; 11(10): 5222–5228.
Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002; 100(12):4129–4138.
Twizere JC, Kruys V, Lefebvre L, et al. Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J Natl Cancer Inst 2003; 95(24): 1846–1859.
Seki N, Yamaguchi K, Yamada A, et al. Polymorphism of the 5’-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J INFEC DIS 1999; 180:880–883.
Tsukasaki K, Miller CW, Kubota T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001; 61(9):3770–3774.
Ciminale V, D’Agostino D, Zotti L, Franchini G, Felber BK, Chieco-Bianchi L. Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II. Virology 1995; 209:445–456.
Koralnik IJ, Fullen J, Franchini G. The p121, p13II, and p30II proteins encoded by human T-cell leukemia/lymphotropic virus type I open reading frames I and II are localized in three different cellular compartments. J Virol 1993; 67(4):2360–2366.
Koralnik IJ, Gessain A, Klotman ME, Lo MA, Berneman ZN, Franchini G. Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc Natl Acad Sci U S A 1992; 89(18):8813–8817.
Berneman ZN, Gartenhaus RB, Reitz MS, et al. Expression of alternatively spliced human T-lymphotropic virus type 1 pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia/lymphoma and healthy carriers. Proc Natl Acad Sci USA 1992; 89:3005–3009.
Derse D, Mikovits J, Ruscetti F. X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro. Virology 1997; 237:123–128.
Kim SJ, Ding W, Albrecht B, Green PL, Lairmore MD. A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated T cell activation. J Biol Chem 2003; 278(18): 15550–15557.
Albrecht B, D’Souza CD, Ding W, Tridandapani S, Coggeshall KM, Lairmore MD. Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein pl2(I). J Virol 2002; 76(7):3493–3501.
Ding W, Albrecht B, Kelley RE et al. Human T-cell lymphotropic virus type 1 pl2(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells. J Virol 2002; 76(20): 10374–10382.
Zhang W, Nisbet JW, Albrecht B et al. Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300. J Virol 2001; 75(20):9885–9895.
Bartoe JT, Albrecht B, Collins ND et al. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol 2000; 74:1094–1100.
Lairmore MD, Albrecht B, D’Souza C, et al. In vitro and in vivo functional analysis of human T cell lymphotropic virus type 1 pX open reading frames I and II. AIDS Res Hum Retroviruses 2000; 16(16): 1757–1764.
Zhang W, Nisbet JW, Bartoe JT, Ding W, Lairmore MD. Human T-lymphotropic virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive promoters. J Virol 2000;74(23):11270–11277.
Albrecht B, Collins ND, Burniston MT. et al. Human T-lymphotropic virus type 1 open reading frame I pl2(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74(21): 9828–9835.
Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998; 91(12): 4701–4707.
Johnson JM, Franchini G. Retroviral proteins that target the major histocompatibility complex class I. Virus Res 2002; 88(1–2):119–127.
Dekaban GA, Peters AA, Mulloy JC, et al. The HTLV-I orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits. Virology 2000; 274(1): 86–93.
D’Agostino DM, Zotti L, Ferro T, Franchini G, Chieco-Bianchi L, Ciminale V. The pl3II protein of HTLV type 1: comparison with mitochondrial proteins coded by other human viruses. AIDS Res Hum Retroviruses 2000; 16(16):1765–1770.
Ciminale V, Zotti L, D’Agostino DM, et al. Mitochondrial targeting of the pl3(II) protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I). Oncogene 1999; 18:4505–4514.
Trovato R, Mulloy JC, Johnson JM, Takemoto S, de Oliveira MP, Franchini G. A lysine-to-arginine change found in natural alleles of the human T-cell lymphotropic/leukemia virus type 1 p12(I) protein greatly influences its stability. J Virol 1999; 73(8):6460–6467.
Ciminale V, Pavlakis GN, Derse D, Cunningham CP, Felber BK. Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: Novel mRNAs and proteins produced by HTLV type I. J Virol 1992; 66:1737–1745.
Furukawa K, Furukawa K, Shiku H. Alternatively spliced mRNA of the pX region of human T lymphotropic virus type I proviral genome. FEBS Lett 1991; 295(1–3):141–145.
Cereseto A, Berneman Z, Koralnik I, Vaughn J, Franchini G, Klotman ME. Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Leukemia 1997; 11(6):866–870.
Ding W, Albrecht B, Luo R et al. Endoplasmic Reticulum and cis-Golgi Localization of Human T-Lymphotropic Virus Type 1 p12(I): Association with Calreticulin and Calnexin. J Virol 2001; 75(16): 7672–7682.
Nicot C, Mulloy JC, Ferrari MG et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001; 98(3):823–829.
Ballard DW. Molecular mechanisms in lymphocyte activation and growth. Immunol Res 2001; 23(2–3):157–166.
Ding W, Kim SJ, Nair AM et al. Human T-Cell Lymphotropic Virus Type 1 p12(I) Enhances Interleukin-2 Production during T-Cell Activation. J Virol 2003; 77(20): 11027–11039.
vonBulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278(5335): 138–141.
Vogel KW, Briesewitz R, Wandless TJ, Crabtree GR. Calcineurin inhibitors and the generalization of the presenting protein strategy. Adv Protein Chem 2001; 56:253–291.
Crabtree GR. Calcium, calcineurin, and the control of transcription. J Biol Chem 2001; 276(4): 2313–2316.
Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 2001; 19:497–521.
Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285(5436): 2129–2133.
Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol 2001; 2(4):316–324.
Aramburu J, Rao A, Klee CB. Calcineurin: from structure to function. Curr Top Cell Regul 2000; 36:237–295.
Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997; 15:707–747.
Tokumitsu H, Enslen H, Soderling TR. Characterization of a Ca2+/calmodulin-dependent protein kinase cascade. Molecular cloning and expression of calcium/calmodulin-dependent protein kinase kinase. J Biol Chem 1995; 270(33): 19320–19324.
Dolmetsch RE, Lewis RS, Goodnow CC, Healy JL Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 1997; 386(6627):855–858.
Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998; 392(6679):933–936.
Li W, Llopis J, Whitney M, Zlokarnik G, Tsien RY. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Nature 1998; 392(6679):936–941.
Nyland SB, Cao C, Bai Y, Loughran TP, Ugen KE. Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J Acquir Immune Defic Syndr 2003; 32(4):406–416.
Koga H, Imada K, Ueda M, Hishizawa M, Uchiyama T. Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo. Cancer Sci 2004; 95(5):411–417.
Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev 2002; 66(3):396–406.
Silic-Benussi M, Cavallari I, Zorzan T, et al. Suppression of tumor growth and cell proliferation by pl3II, a mitochondrial protein of human T cell leukemia virus type 1. Proc Natl Acad Sci U S A 2004; 101(17):6629–6634.
Nicot C, Dundr M, Johnson JM, et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004; 10(2): 197–201.
Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD. Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol 2004; 78(8):3837–3845.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this chapter
Cite this chapter
Lairmore, M.D., Ratner, L. (2007). HTLV-1, Cytokines,and Cancer. In: Caligiuri, M.A., Lotze, M.T. (eds) Cytokines in the Genesis and Treatment of Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-455-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-455-1_2
Publisher Name: Humana Press
Print ISBN: 978-0-89603-820-2
Online ISBN: 978-1-59745-455-1
eBook Packages: MedicineMedicine (R0)